Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
2.
Neurology ; 100(18): 868-878, 2023 05 02.
Article in English | MEDLINE | ID: mdl-36639235

ABSTRACT

Music-based interventions (MBIs) show promise for managing symptoms of various brain disorders. To fully realize the potential of MBIs and dispel the outdated misconception that MBIs are rooted in soft science, the NIH is promoting rigorously designed, well-powered MBI clinical trials. The pressing need of guidelines for scientifically rigorous studies with enhanced data collection brought together the Renée Fleming Foundation, the Foundation for the NIH, the Trans-NIH Music and Health Working Group, and an interdisciplinary scientific expert panel to create the NIH MBI Toolkit for research on music and health across the lifespan. The Toolkit defines the building blocks of MBIs, including a consolidated set of common data elements for MBI protocols, and core datasets of outcome measures and biomarkers for brain disorders of aging that researchers may select for their studies. Utilization of the guiding principles in this Toolkit will be strongly recommended for NIH-funded studies of MBIs.


Subject(s)
Brain Diseases , Mindfulness , Music , Humans , Mindfulness/methods , Data Collection , Aging
3.
Brain ; 134(Pt 6): 1591-609, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21482550

ABSTRACT

Neuroplasticity can be defined as the ability of the nervous system to respond to intrinsic or extrinsic stimuli by reorganizing its structure, function and connections. Major advances in the understanding of neuroplasticity have to date yielded few established interventions. To advance the translation of neuroplasticity research towards clinical applications, the National Institutes of Health Blueprint for Neuroscience Research sponsored a workshop in 2009. Basic and clinical researchers in disciplines from central nervous system injury/stroke, mental/addictive disorders, paediatric/developmental disorders and neurodegeneration/ageing identified cardinal examples of neuroplasticity, underlying mechanisms, therapeutic implications and common denominators. Promising therapies that may enhance training-induced cognitive and motor learning, such as brain stimulation and neuropharmacological interventions, were identified, along with questions of how best to use this body of information to reduce human disability. Improved understanding of adaptive mechanisms at every level, from molecules to synapses, to networks, to behaviour, can be gained from iterative collaborations between basic and clinical researchers. Lessons can be gleaned from studying fields related to plasticity, such as development, critical periods, learning and response to disease. Improved means of assessing neuroplasticity in humans, including biomarkers for predicting and monitoring treatment response, are needed. Neuroplasticity occurs with many variations, in many forms, and in many contexts. However, common themes in plasticity that emerge across diverse central nervous system conditions include experience dependence, time sensitivity and the importance of motivation and attention. Integration of information across disciplines should enhance opportunities for the translation of neuroplasticity and circuit retraining research into effective clinical therapies.


Subject(s)
Biomedical Research , Brain Diseases/physiopathology , Brain Diseases/therapy , Neuronal Plasticity/physiology , Aging , Animals , Cognition Disorders/etiology , Humans , Recovery of Function , Stroke/pathology , Stroke/physiopathology , Stroke/therapy
4.
Pain Med ; 12(9): 1336-57, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21834914

ABSTRACT

OBJECTIVE: There has been a growing recognition of the need for better pharmacologic management of chronic pain among older adults. To address this need, the National Institutes of Health Pain Consortium sponsored an "Expert Panel Discussion on the Pharmacological Management of Chronic Pain in Older Adults" conference in September 2010 to identify research gaps and strategies to address them. Specific emphasis was placed on ascertaining gaps regarding use of opioid and nonsteroidal anti-inflammatory medications because of continued uncertainties regarding their risks and benefits. DESIGN: Eighteen panel members provided oral presentations; each was followed by a multidisciplinary panel discussion. Meeting transcripts and panelists' slide presentations were reviewed to identify the gaps and the types of studies and research methods panelists suggested could best address them. RESULTS: Fifteen gaps were identified in the areas of treatment (e.g., uncertainty regarding the long-term safety and efficacy of commonly prescribed analgesics), epidemiology (e.g., lack of knowledge regarding the course of common pain syndromes), and implementation (e.g., limited understanding of optimal strategies to translate evidence-based pain treatments into practice). Analyses of data from electronic health care databases, observational cohort studies, and ongoing cohort studies (augmented with pain and other relevant outcomes measures) were felt to be practical methods for building an age-appropriate evidence base to improve the pharmacologic management of pain in later life. CONCLUSION: Addressing the gaps presented in the current report was judged by the panel to have substantial potential to improve the health and well-being of older adults with chronic pain.


Subject(s)
Analgesia/methods , Analgesia/standards , Analgesics/standards , Analgesics/therapeutic use , Pain, Intractable/drug therapy , Aged , Aged, 80 and over , Biomedical Research/trends , Evidence-Based Medicine/standards , Humans , Pain, Intractable/epidemiology , Pain, Intractable/physiopathology
5.
Trends Neurosci ; 44(1): 3-16, 2021 01.
Article in English | MEDLINE | ID: mdl-33378655

ABSTRACT

Interoception refers to the representation of the internal states of an organism, and includes the processes by which it senses, interprets, integrates, and regulates signals from within itself. This review presents a unified research framework and attempts to offer definitions for key terms to describe the processes involved in interoception. We elaborate on these definitions through illustrative research findings, and provide brief overviews of central aspects of interoception, including the anatomy and function of neural and non-neural pathways, diseases and disorders, manipulations and interventions, and predictive modeling. We conclude with discussions about major research gaps and challenges.


Subject(s)
Interoception , Humans
6.
Neuron ; 52(2): 255-69, 2006 Oct 19.
Article in English | MEDLINE | ID: mdl-17046689

ABSTRACT

Mutations or duplications in MECP2 cause Rett and Rett-like syndromes, neurodevelopmental disorders characterized by mental retardation, motor dysfunction, and autistic behaviors. MeCP2 is expressed in many mammalian tissues and functions as a global repressor of transcription; however, the molecular mechanisms by which MeCP2 dysfunction leads to the neural-specific phenotypes of RTT remain poorly understood. Here, we show that neuronal activity and subsequent calcium influx trigger the de novo phosphorylation of MeCP2 at serine 421 (S421) by a CaMKII-dependent mechanism. MeCP2 S421 phosphorylation is induced selectively in the brain in response to physiological stimuli. Significantly, we find that S421 phosphorylation controls the ability of MeCP2 to regulate dendritic patterning, spine morphogenesis, and the activity-dependent induction of Bdnf transcription. These findings suggest that, by triggering MeCP2 phosphorylation, neuronal activity regulates a program of gene expression that mediates nervous system maturation and that disruption of this process in individuals with mutations in MeCP2 may underlie the neural-specific pathology of RTT.


Subject(s)
Brain-Derived Neurotrophic Factor/biosynthesis , Brain/growth & development , Brain/metabolism , Cell Differentiation/physiology , Dendritic Spines/metabolism , Methyl-CpG-Binding Protein 2/metabolism , Animals , Brain/cytology , Brain-Derived Neurotrophic Factor/genetics , Calcium Signaling/physiology , Calcium-Calmodulin-Dependent Protein Kinase Type 2 , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Dendritic Spines/ultrastructure , Gene Expression Regulation, Developmental/physiology , Methyl-CpG-Binding Protein 2/genetics , Neural Pathways/cytology , Neural Pathways/growth & development , Neural Pathways/metabolism , Neuronal Plasticity/physiology , Organ Culture Techniques , Organ Specificity/physiology , Phosphorylation , Rats , Rett Syndrome/genetics , Rett Syndrome/metabolism , Rett Syndrome/physiopathology , Serine/metabolism , Synaptic Transmission/physiology
7.
Neuron ; 33(3): 383-95, 2002 Jan 31.
Article in English | MEDLINE | ID: mdl-11832226

ABSTRACT

Transcription of the brain-derived neurotrophic factor (BDNF) gene is regulated in a calcium- and neuron-selective manner; however, the mechanisms that underlie this selectivity are not known. We have characterized a new calcium-response element, CaRE1, that is required for activity-dependent transcription of BDNF exon III and have cloned a transcription factor, CaRF, that activates transcription from BDNF promoter III in a CaRE1-dependent manner. The transcriptional activity of CaRF is regulated in a calcium- and neuron-selective manner, suggesting that CaRF may confer selectivity upon the activity-dependent induction of BDNF exon III expression.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Gene Expression Regulation/physiology , Neurons/metabolism , Response Elements/genetics , Transcription Factors/metabolism , 1-Methyl-3-isobutylxanthine/pharmacology , Amino Acid Sequence , Animals , Brain/cytology , Brain/metabolism , Brain-Derived Neurotrophic Factor/genetics , Calcium/metabolism , Cells, Cultured , Cyclic AMP/analogs & derivatives , Cyclic AMP/metabolism , DNA-Binding Proteins , Exons/genetics , Genes, Reporter , Humans , In Situ Hybridization , Microscopy, Fluorescence , Molecular Sequence Data , Neurons/cytology , Neurons/drug effects , Nuclear Proteins/metabolism , Phosphodiesterase Inhibitors/pharmacology , Rats , Rats, Long-Evans , Regulatory Sequences, Nucleic Acid/genetics , Tissue Distribution , Transcription Factors/chemistry , Two-Hybrid System Techniques
8.
J Gerontol A Biol Sci Med Sci ; 71(11): 1451-1458, 2016 11.
Article in English | MEDLINE | ID: mdl-27154905

ABSTRACT

BACKGROUND: Research suggests that the central nervous system (CNS) and mobility are closely linked. CNS-mediated mobility impairment may represent a potentially new and prevalent syndrome within the older adult populations. Interventions targeting this group may have the potential to improve mobility and cognition and prevent disability. METHODS: In 2012, the Gerontological Society of America (GSA) and the National Institute on Aging (NIA) sponsored a 3-year conference workshop series, "Aging, the CNS, and Mobility." The goal of this third and final conference was to (i) report on the state of the science of interventions targeting CNS-mediated mobility impairment among community-dwelling older adults and (ii) partnering with the NIA, explore the future of research and intervention design focused on a potentially novel aging syndrome. RESULTS: Evidence was presented in five main intervention areas: (i) pharmacology and diet; (ii) exercise; (iii) electrical stimulation; (iv) sensory stimulation/deprivation; and (v) a combined category of multimodal interventions. Workshop participants identified important gaps in knowledge and key recommendations for future interventions related to recruitment and sample selection, intervention design, and methods to measure effectiveness. CONCLUSIONS: In order to develop effective preventive interventions for this prevalent syndrome, multidisciplinary teams are essential particularly because of the complex nature of the syndrome. Additionally, integrating innovative methods into the design of interventions may help researchers better measure complex mechanisms, and finally, the value of understanding the link between the CNS and mobility should be conveyed to researchers across disciplines in order to incorporate cognitive and mobility measurements into study protocols.


Subject(s)
Aging/physiology , Central Nervous System/physiopathology , Mobility Limitation , Aged , Congresses as Topic , Disability Evaluation , Geriatric Assessment , Humans , Risk Factors , Societies, Medical , United States
9.
J Neurosci ; 24(33): 7366-77, 2004 Aug 18.
Article in English | MEDLINE | ID: mdl-15317862

ABSTRACT

Local regulation of mRNA translation plays an important role in axon guidance, synaptic development, and neuronal plasticity. Little is known, however, regarding the mechanisms that control translation in neurons, and only a few mRNAs have been identified that are locally translated within axon and dendrites. Using Affymetrix gene arrays to identify mRNAs that are newly associated with polysomes after exposure to BDNF, we identified subsets of mRNAs for which translation is enhanced in neurons at different developmental stages. In mature neurons, many of these mRNAs encode proteins that are known to function at synapses, including CamKIIalpha, NMDA receptor subunits, and the postsynaptic density (PSD) scaffolding protein Homer2. BDNF regulates the translation of Homer2 locally in the synaptodendritic compartment by activating translational initiation via a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway. These findings suggest that BDNF likely regulates synaptic function by inducing the local synthesis of numerous synaptic proteins. The local translation of the cytoskeleton-associated protein Homer2 in particular might have important implications for growth cone dynamics and dendritic spine development.


Subject(s)
Brain-Derived Neurotrophic Factor/pharmacology , Brain/embryology , Neurons/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein Biosynthesis , Protein Kinases/metabolism , Animals , Brain/cytology , Carrier Proteins/analysis , Carrier Proteins/biosynthesis , Carrier Proteins/genetics , Dendrites/chemistry , Gene Expression Profiling , Gene Expression Regulation , Homer Scaffolding Proteins , Neurons/drug effects , Neurons/enzymology , Polyribosomes/drug effects , Polyribosomes/genetics , RNA, Messenger/analysis , RNA, Messenger/classification , Rats , Rats, Long-Evans , Signal Transduction , Synapses/chemistry , Synapses/metabolism , Synapses/ultrastructure , TOR Serine-Threonine Kinases
10.
J Neurosci ; 23(7): 2572-81, 2003 Apr 01.
Article in English | MEDLINE | ID: mdl-12684442

ABSTRACT

To identify molecular mechanisms that control activity-dependent gene expression in the CNS, we have characterized the factors that mediate activity-dependent transcription of BDNF promoter III. We report the identification of a Ca(2+)-responsive E-box element, CaRE2, within BDNF promoter III that binds upstream stimulatory factors 1 and 2 (USF1/2) and show that USFs are required for the activation of CaRE2-dependent transcription from BDNF promoter III. We find that the transcriptional activity of the USFs is regulated by Ca(2+)-activated signaling pathways in neurons and that the USFs bind to the promoters of a number of neuronal activity-regulated genes in vivo. These results suggest a new function for the USFs in the regulation of activity-dependent transcription in neurons.


Subject(s)
Brain-Derived Neurotrophic Factor/genetics , Calcium Signaling , Neurons/metabolism , Transcription Factors/physiology , Transcriptional Activation , Animals , Base Sequence , Binding Sites , Calcium Channels, L-Type/physiology , Cells, Cultured , Central Nervous System/metabolism , Cloning, Molecular , DNA-Binding Proteins/genetics , Exons , Mice , Promoter Regions, Genetic , Rats , Rats, Long-Evans , Response Elements , Transcription Factors/genetics , Upstream Stimulatory Factors
11.
J Gerontol A Biol Sci Med Sci ; 70(12): 1526-32, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26386013

ABSTRACT

BACKGROUND: Mobility is crucial for successful aging and is impaired in many older adults. We know very little about the subtle, subclinical age-related changes in the central nervous system (CNS) that mediate mobility impairment. METHODS: A conference series focused on aging, the CNS, and mobility was launched. The second conference addressed major age-associated mechanisms of CNS-mediated mobility impairment. Speakers and conference attendees recommended key areas for future research, identified barriers to progress, and proposed strategies to overcome them. RESULTS: Priorities identified for future research include (a) studying interactions among different mechanisms; (b) examining effects of interventions targeting these mechanisms; (c) evaluating the effect of genetic polymorphisms on risks and course of age-related mobility impairment; and (d) examining the effect of age on CNS repair processes, neuroplasticity, and neuronal compensatory mechanisms. Key strategies to promote research include (a) establish standard measures of mobility across species; (b) evaluate the effect of aging in the absence of disease on CNS and mobility; and (c) use advanced computational methods to better evaluate the interactions between CNS and other systems involved in mobility. CONCLUSIONS: CNS is a major player in the process, leading to mobility decline with aging. Future research in this area has the potential to prolong independence in older persons. Better interactions among disciplines and shared research paradigms are needed to make progress. Research priorities include the development of innovative approaches to integrate research on aging, cognition, and movement with attention to neurovascular function, neuroplasticity, and neurophysiological reserve.


Subject(s)
Aging/physiology , Central Nervous System/physiopathology , Mobility Limitation , Aged , Aging/genetics , Aging/metabolism , Humans , Inflammation/physiopathology , Practice Guidelines as Topic
12.
Expert Rev Proteomics ; 1(3): 343-54, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15966830

ABSTRACT

Protein phosphorylation events are key regulators of cellular signaling processes. In the era of functional genomics, rational drug design programs demand large-scale high-throughput analysis of signal transduction cascades. Significant improvements in the area of mass spectrometry-based proteomics have provided exciting opportunities for rapid progress toward global protein phosphorylation analysis. This review summarizes several recent advances made in the field of phosphoproteomics with an emphasis placed on mass spectrometry instrumentation, enrichment methods and quantification strategies. In the near future, these technologies will provide a tool that can be used for quantitative investigation of signal transduction pathways to generate new insights into biologic systems.


Subject(s)
Cell Physiological Phenomena , Proteins/physiology , Proteomics/methods , Signal Transduction/physiology , Animals , Humans , Mass Spectrometry , Proteins/chemistry , Proteins/isolation & purification
14.
J Pain ; 14(2): 103-13, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23374939

ABSTRACT

UNLABELLED: Use of opioid analgesics for pain management has increased dramatically over the past decade, with corresponding increases in negative sequelae including overdose and death. There is currently no well-validated objective means of accurately identifying patients likely to experience good analgesia with low side effects and abuse risk prior to initiating opioid therapy. This paper discusses the concept of data-based personalized prescribing of opioid analgesics as a means to achieve this goal. Strengths, weaknesses, and potential synergism of traditional randomized placebo-controlled trial (RCT) and practice-based evidence (PBE) methodologies as means to acquire the clinical data necessary to develop validated personalized analgesic-prescribing algorithms are overviewed. Several predictive factors that might be incorporated into such algorithms are briefly discussed, including genetic factors, differences in brain structure and function, differences in neurotransmitter pathways, and patient phenotypic variables such as negative affect, sex, and pain sensitivity. Currently available research is insufficient to inform development of quantitative analgesic-prescribing algorithms. However, responder subtype analyses made practical by the large numbers of chronic pain patients in proposed collaborative PBE pain registries, in conjunction with follow-up validation RCTs, may eventually permit development of clinically useful analgesic-prescribing algorithms. PERSPECTIVE: Current research is insufficient to base opioid analgesic prescribing on patient characteristics. Collaborative PBE studies in large, diverse pain patient samples in conjunction with follow-up RCTs may permit development of quantitative analgesic-prescribing algorithms that could optimize opioid analgesic effectiveness and mitigate risks of opioid-related abuse and mortality.


Subject(s)
Analgesics, Opioid/therapeutic use , Chronic Pain/drug therapy , Drug Prescriptions , Precision Medicine/methods , Biomarkers , Biomedical Research , Chronic Pain/genetics , Chronic Pain/psychology , Drug Synergism , Genetic Variation , Humans , Neurotransmitter Agents/metabolism , Neurotransmitter Agents/physiology , Randomized Controlled Trials as Topic
15.
J Gerontol A Biol Sci Med Sci ; 68(11): 1379-86, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23843270

ABSTRACT

BACKGROUND: Mobility limitations are common and hazardous in community-dwelling older adults but are largely understudied, particularly regarding the role of the central nervous system (CNS). This has limited development of clearly defined pathophysiology, clinical terminology, and effective treatments. Understanding how changes in the CNS contribute to mobility limitations has the potential to inform future intervention studies. METHODS: A conference series was launched at the 2012 conference of the Gerontological Society of America in collaboration with the National Institute on Aging and the University of Pittsburgh. The overarching goal of the conference series is to facilitate the translation of research results into interventions that improve mobility for older adults. RESULTS: Evidence from basic, clinical, and epidemiological studies supports the CNS as an important contributor to mobility limitations in older adults without overt neurologic disease. Three main goals for future work that emerged were as follows: (a) develop models of mobility limitations in older adults that differentiate aging from disease-related processes and that fully integrate CNS with musculoskeletal contributors; (b) quantify the contribution of the CNS to mobility loss in older adults in the absence of overt neurologic diseases; (c) promote cross-disciplinary collaboration to generate new ideas and address current methodological issues and barriers, including real-world mobility measures and life-course approaches. CONCLUSIONS: In addition to greater cross-disciplinary research, there is a need for new approaches to training clinicians and investigators, which integrate concepts and methodologies from individual disciplines, focus on emerging methodologies, and prepare investigators to assess complex, multisystem associations.


Subject(s)
Aging/physiology , Central Nervous System/physiology , Mobility Limitation , Gait/physiology , Humans
17.
Science ; 302(5646): 885-9, 2003 Oct 31.
Article in English | MEDLINE | ID: mdl-14593183

ABSTRACT

Mutations in MeCP2, which encodes a protein that has been proposed to function as a global transcriptional repressor, are the cause of Rett syndrome (RT T), an X-linked progressive neurological disorder. Although the selective inactivation of MeCP2 in neurons is sufficient to confer a Rett-like phenotype in mice, the specific functions of MeCP2 in postmitotic neurons are not known. We find that MeCP2 binds selectively to BDNF promoter III and functions to repress expression of the BDNF gene. Membrane depolarization triggers the calcium-dependent phosphorylation and release of MeCP2 from BDNF promoter III, thereby facilitating transcription. These studies indicate that MeCP2 plays a key role in the control of neuronal activity-dependent gene regulation and suggest that the deregulation of this process may underlie the pathology of RT T.


Subject(s)
Brain-Derived Neurotrophic Factor/genetics , Calcium/metabolism , Chromosomal Proteins, Non-Histone , DNA-Binding Proteins/metabolism , Gene Expression Regulation , Repressor Proteins , Transcription, Genetic , Animals , Cell Membrane/physiology , Cells, Cultured , Cloning, Molecular , CpG Islands , DNA Methylation , Electrophoretic Mobility Shift Assay , Gene Silencing , Histones/metabolism , Methyl-CpG-Binding Protein 2 , Methylation , Mice , Mice, Knockout , Neurons/metabolism , Neurons/physiology , Phosphorylation , Potassium Chloride/pharmacology , Precipitin Tests , Promoter Regions, Genetic , Rats , Rett Syndrome/genetics
SELECTION OF CITATIONS
SEARCH DETAIL